GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates

Regulatory News:GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial resul…